This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a University of British Columbia directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $699,380
A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer: SABR-COMET-3
CIHR · 2019 · Principal investigator
A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer: SABR-COMET-3
Principal investigators: Olson, Robert A; Allan, Alison L; Palma, David; Peacock, Stuart J; Tyldesley, Scott K
Keywords: Biomarkers; Cost-Effectiveness/Cost-Utility; Metastatic Cancers; Oligometastatic Disease/State; Overall Survival; Progression-Free Survival; Quality Of Life; Quality-Adjusted Life Years; Stereotactic Radiotherapy; Toxicity
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.